Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference

This document summarizes recommendations from a state-of-the-art conference convened to evaluate the role of nucleoside analogue reverse transcriptase inhibitors in the treatment of human immunodeficiency virus (HIV) infection. Data from controlled clinical trials of zidovudine, didanosine, and zalcitabine were reviewed by an expert panel, which then formulated guidelines to assist clinicians and HIV-infected patients in the use of these agents. Recommendations were framed in the context of clinical scenarios for patients with asymptomatic HIV infection who have not had prior antiretroviral therapy; those with signs and symptoms of HIV-related disease who have not received prior therapy; clinically stable patients who are tolerating initial zidovudine therapy; patients experiencing clinical progression while on zidovudine therapy; and those who are intolerant of antiretroviral therapy. The panel concluded that physicians need to integrate up-to-date scientific knowledge with other relevant needs to improve the care of HIV-infected patients. ( JAMA . 1993;270:2583-2589)

[1]  P. Volberding,et al.  Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection , 1993, Annals of Internal Medicine.

[2]  J. Gatell,et al.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter , 1993 .

[3]  M. Fischl,et al.  Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy , 1993, Annals of Internal Medicine.

[4]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[5]  J. Aboulker,et al.  Preliminary analysis of the Concorde trial , 1993, The Lancet.

[6]  T. Merigan,et al.  Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients with AIDS or AIDS-Related Complex , 1993, Annals of Internal Medicine.

[7]  P. Gøtzsche,et al.  [Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group]. , 1993, Ugeskrift for laeger.

[8]  D. Richman,et al.  Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection , 1992, Annals of Internal Medicine.

[9]  J. Darbyshire,et al.  Didanosine for zidovudine-intolerant patients with HIV disease , 1992, The Lancet.

[10]  S. Hammer,et al.  Zidovudine: Five Years Later , 1992, Annals of Internal Medicine.

[11]  T. Merigan,et al.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[12]  G L Drusano,et al.  A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. , 1992, The New England journal of medicine.

[13]  M. Wulfsohn,et al.  A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome , 1990 .

[14]  Douglas D. Richman,et al.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial , 1990 .

[15]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[16]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.